We are pleased to share that Neuronostics has raised £3M in new investment, co-led by @Empirical Ventures and @The FSE Group, with support from @Ascension Ventures, @QantX, @New Wave Venture Partners and @Angel Investors Bristol, alongside a £400K @Innovate UK Investor Partnerships grant.

This investment enables three priorities: expand access to BioEP across UK epilepsy services, preparing our FDA submission for the US market, and extending our digital biomarker platform to Pharma and other neurological indications.

A big thank you to our investors, partners and everyone who has supported us on this journey so far.

Read the full announcement here.